Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling.

DMD MV-MMCT T-iPSC aneuploidy syndrome gene and cell therapy human artificial chromosome

Journal

Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621

Informations de publication

Date de publication:
05 Mar 2021
Historique:
received: 29 06 2020
accepted: 11 12 2020
entrez: 8 2 2021
pubmed: 9 2 2021
medline: 9 2 2021
Statut: epublish

Résumé

Genetic engineering of induced pluripotent stem cells (iPSCs) holds great promise for gene and cell therapy as well as drug discovery. However, there are potential concerns regarding the safety and control of gene expression using conventional vectors such as viruses and plasmids. Although human artificial chromosome (HAC) vectors have several advantages as a gene delivery vector, including stable episomal maintenance and the ability to carry large gene inserts, the full potential of HAC transfer into iPSCs still needs to be explored. Here, we provide evidence of a HAC transfer into human iPSCs by microcell-mediated chromosome transfer via measles virus envelope proteins for various applications, including gene and cell therapy, establishment of versatile human iPSCs capable of gene loading and differentiation into T cells, and disease modeling for aneuploidy syndrome. Thus, engineering of human iPSCs via desired HAC vectors is expected to be widely applied in biomedical research.

Identifiants

pubmed: 33552683
doi: 10.1016/j.omtn.2020.12.012
pii: S2162-2531(20)30393-0
pmc: PMC7819819
doi:

Types de publication

Journal Article

Langues

eng

Pagination

629-639

Subventions

Organisme : Medical Research Council
ID : MR/J006785/1
Pays : United Kingdom

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

K.F., S. Takayanagi, and A.K. are employed by Kirin Holdings, Co., Ltd. S.N. is employed by Kyowa Kirin, Co., Ltd. The other authors declare no competing interests.

Références

Mol Ther. 2011 Sep;19(9):1591-601
pubmed: 21750534
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4
pubmed: 30449714
Hum Mol Genet. 1994 Aug;3(8):1245-57
pubmed: 7987298
Biochem Biophys Res Commun. 2004 Apr 30;317(2):491-9
pubmed: 15063784
Cells. 2018 Dec 08;7(12):
pubmed: 30544831
PLoS One. 2011 Feb 24;6(2):e17267
pubmed: 21390305
Mol Ther. 2010 Feb;18(2):386-93
pubmed: 19997091
Sci Transl Med. 2012 Jun 27;4(140):140ra89
pubmed: 22745439
Sci Transl Med. 2011 Aug 17;3(96):96ra78
pubmed: 21849666
Cell Stem Cell. 2013 May 2;12(5):559-72
pubmed: 23642365
Cell Mol Life Sci. 2013 Apr;70(7):1135-48
pubmed: 22907415
Chromosome Res. 2015 Feb;23(1):135-41
pubmed: 25596829
Mol Ther Methods Clin Dev. 2014 Jan 08;1:1
pubmed: 26015941
J Hum Genet. 2001;46(3):137-45
pubmed: 11310581
Cytotechnology. 2018 Dec;70(6):1499-1508
pubmed: 30112660
Physiol Rev. 2019 Jan 1;99(1):79-114
pubmed: 30328784
Chromosome Res. 2015 Feb;23(1):111-33
pubmed: 25657031
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):722-7
pubmed: 10639146
PLoS One. 2016 Jun 07;11(6):e0157187
pubmed: 27271046
Mol Ther. 2016 Apr;24(4):678-84
pubmed: 26867951
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9962-7
pubmed: 23716668
Biol Methods Protoc. 2018 Dec 31;3(1):bpy013
pubmed: 32161806
Hum Mol Genet. 2013 Feb 1;22(3):578-92
pubmed: 23125282
Cell Rep. 2012 Dec 27;2(6):1722-35
pubmed: 23219550
Stem Cell Reports. 2017 Apr 11;8(4):803-812
pubmed: 28344001
Cell Stem Cell. 2013 Jan 3;12(1):114-26
pubmed: 23290140
PLoS One. 2011;6(10):e25961
pubmed: 21998730
PLoS One. 2018 Mar 5;13(3):e0193642
pubmed: 29505588
BMC Biotechnol. 2015 Jun 19;15:58
pubmed: 26088202
BMC Biotechnol. 2010 May 06;10:37
pubmed: 20444293
Cell Rep. 2016 Jun 7;15(10):2301-2312
pubmed: 27239027
Mol Ther Methods Clin Dev. 2016 Jun 22;3:16043
pubmed: 27382603
Hum Mol Genet. 2001 May 15;10(11):1163-75
pubmed: 11371509
Exp Cell Res. 2020 May 1;390(1):111915
pubmed: 32092294
Mol Ther Methods Clin Dev. 2020 Jan 21;17:369-377
pubmed: 32099849
Nat Genet. 1997 Jun;16(2):133-43
pubmed: 9171824
EMBO Mol Med. 2018 Feb;10(2):254-275
pubmed: 29242210
Gene Ther. 2011 Apr;18(4):384-93
pubmed: 21085194
Nature. 2015 May 7;521(7550):43-7
pubmed: 25924068
Nat Protoc. 2015 Jul;10(7):941-58
pubmed: 26042384
Nat Biotechnol. 2002 Sep;20(9):889-94
pubmed: 12172556
PLoS One. 2014 Oct 10;9(10):e110404
pubmed: 25303219
Cell Stem Cell. 2008 Nov 6;3(5):519-32
pubmed: 18983967
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348-62
pubmed: 19838014
Nat Med. 2015 Mar;21(3):256-62
pubmed: 25706875

Auteurs

Yasuhiro Kazuki (Y)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.
Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Narumi Uno (N)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.
Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.
Laboratory of Bioengineering, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo 192-0392, Japan.

Satoshi Abe (S)

Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Naoyo Kajitani (N)

Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Kanako Kazuki (K)

Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Yuwna Yakura (Y)

Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Chiaki Sawada (C)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Shuta Takata (S)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Masaki Sugawara (M)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Yuichi Nagashima (Y)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Akane Okada (A)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Masaharu Hiratsuka (M)

Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Mitsuhiko Osaki (M)

Division of Experimental Pathology, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Giulia Ferrari (G)

Department of Cell and Developmental Biology, University College London, London WC1E 6DE, UK.

Francesco Saverio Tedesco (FS)

Department of Cell and Developmental Biology, University College London, London WC1E 6DE, UK.
Dubowitz Neuromuscular Centre, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
The Francis Crick Institute, London NW1 1AT, UK.

Satoshi Nishikawa (S)

Regenerative Medicine Research Laboratories, Research Functions Unit, R&D Division, Kyowa Kirin, Co., Ltd. 3-6-6, Asahi-machi, Machida-shi, Tokyo 194-8533, Japan.

Ken Fukumoto (K)

Cell Therapy Project, R&D Division, Kirin Holdings, Co., Ltd. 1-13-5, Fukuura Kanazawa-ku, Yokohama, Kanagawa 236-0004 Japan.

Shin-Ichiro Takayanagi (SI)

Cell Therapy Project, R&D Division, Kirin Holdings, Co., Ltd. 1-13-5, Fukuura Kanazawa-ku, Yokohama, Kanagawa 236-0004 Japan.

Atsushi Kunisato (A)

Project Planning Section, Kirin Holdings, Co., Ltd., 4-10-2 Nakano, Nakano-ku, Tokyo 164-0001 Japan.

Shin Kaneko (S)

Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Mitsuo Oshimura (M)

Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan.

Kazuma Tomizuka (K)

Laboratory of Bioengineering, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo 192-0392, Japan.

Classifications MeSH